Comparative Pharmacokinetic Trial of RGB-03 and MabThera
NCT02371096 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2015-02-25
Summary
Pharmacokinetic properties, efficacy, safety and tolerability of RGB-03 and MabThera will be compared in patients suffering from Rheumatoid Arthritis.
Conditions
Interventions
- DRUG
-
MabThera (rituximab)
- DRUG
-
RGB-03
Sponsors & Collaborators
-
Gedeon Richter Plc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Primary Completion
- 2016-06-30
More Related Trials
-
Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis
NCT02296775 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
NCT00422383 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
NCT00845832 ·Status: TERMINATED ·Phase: PHASE2
-
MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
NCT02468791 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT01000610 ·Status: COMPLETED ·Phase: PHASE4
-
A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)
NCT00422942 ·Status: TERMINATED ·Phase: PHASE2
-
PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis
NCT02149121 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis
NCT02693210 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
NCT01715896 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
NCT00424502 ·Status: COMPLETED ·Phase: PHASE4
-
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
NCT02093026 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
NCT00934648 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
NCT00074438 ·Status: COMPLETED ·Phase: PHASE2
-
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
NCT00502996 ·Status: COMPLETED ·Phase: PHASE3
-
MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
NCT04680962 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
NCT04268771 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.
NCT00504777 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
NCT00502853 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
NCT00503425 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
NCT00468546 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
NCT00502840 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
NCT00144508 ·Status: COMPLETED ·Phase: PHASE3
-
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
NCT01526057 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
NCT00462345 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
NCT01390441 ·Status: TERMINATED ·Phase: PHASE1